Blood Screening Market Size, Share, and Trends 2024 to 2034

Blood Screening Market Size and Forecast 2024 to 2034

The global blood screening market size accounted for USD 3.44 billion in 2024 and is expected to be worth around USD 10.41 billion by 2034, at a CAGR of 11.7% from 2024 to 2034. The North America blood screening market size reached USD 1.20 billion in 2023.

Blood Screening Market Key Takeaways

• North America contributed more than 39% of revenue share in 2023.
• Asia-Pacific is estimated to expand the fastest CAGR between 2024 and 2034.
• By technology, the NAT segment held the largest market share of 41% in 2023.
• By technology, the ELISA segment is anticipated to grow at a remarkable CAGR of 12.1% between 2024 and 2034.
• By product, the reagent segment generated over 73% of revenue share in 2023.
• By product, the instrument segment is expected to expand at the fastest CAGR over the projected period.

U.S. Blood Screening Market Size and Growth 2024 to 2034

The U.S. blood screening market size was estimated at USD 842.48 million in 2023 and is predicted to be worth around USD 2,908.36 million by 2034, at a CAGR of 11.9% from 2024 to 2034.

North America has held the largest revenue share of 39% in 2023. North America holds a major share in the blood screening market due to a combination of advanced healthcare infrastructure, high healthcare expenditure, and robust regulatory frameworks. The region's emphasis on preventive healthcare and routine screenings, coupled with a well-established network of diagnostic laboratories and healthcare facilities, contributes to market dominance. Additionally, ongoing technological innovations and the presence of key market players further propel North America as a leader in blood screening, ensuring widespread adoption of advanced screening technologies and services.

Asia-Pacific is estimated to observe the fastest expansion. Asia-Pacific dominates the blood screening market due to its substantial population, rising healthcare awareness, and increasing prevalence of diseases. The region experiences robust economic growth, enabling greater healthcare investments. Moreover, government initiatives promoting preventive healthcare and the implementation of advanced technologies contribute to the market's expansion. The growing demand for diagnostic services, coupled with improving healthcare infrastructure, positions Asia-Pacific as a significant player in the blood screening market, with the potential for further growth and innovation in the coming years.

Market Overview

Blood screening is a vital medical procedure involving the analysis of blood samples to detect and pinpoint various health conditions and irregularities. This diagnostic method furnishes valuable insights into an individual's overall health, aiding in the early identification, prevention, and management of diseases. It encompasses the examination of blood cell counts, the identification of infectious agents like viruses and bacteria, and the measurement of different chemical levels, including cholesterol and glucose.

The significance of blood screening lies in its role as a comprehensive health evaluation tool, enabling healthcare professionals to spot potential issues before symptoms manifest. Routine blood screening is indispensable for diagnosing conditions such as anemia, diabetes, infections, and various cardiovascular diseases. Ongoing technological advancements and the development of specialized blood tests continually enhance the precision and efficiency of screening methods, contributing to improved patient outcomes. Regular blood screening is foundational in proactive healthcare, facilitating timely interventions and fostering overall health and wellness.

Blood Screening Market Growth Factors

• Technological Advancements: Continuous innovations in blood screening technologies, such as advanced analyzers and diagnostic tools, drive market growth by enhancing accuracy and efficiency.
• Rising Disease Awareness: Increasing awareness about the importance of early disease detection fuels demand for blood screening, promoting preventive healthcare practices.
• Aging Population: As the global population ages, the prevalence of diseases that require blood screening, such as cardiovascular conditions and cancers, is on the rise, contributing to market expansion.
• Government Initiatives: Supportive government initiatives and healthcare policies promoting regular blood screening contribute to market growth by encouraging broader adoption.
• Global Pandemic Preparedness: Events like the COVID-19 pandemic underscore the critical role of blood screening in managing infectious diseases, stimulating investments and advancements in the sector.
• Emerging Markets: The expansion of healthcare infrastructure in emerging markets creates new opportunities for blood screening services and products.
• Increasing Healthcare Expenditure: Growth in healthcare spending globally facilitates the adoption of advanced blood screening technologies and services.
• Point-of-Care Testing: The growing demand for point-of-care blood screening solutions accelerates market growth by providing rapid and convenient diagnostic options.
• Personalized Medicine: The trend toward personalized medicine increases the need for precise diagnostic tools, driving advancements and growth in the blood screening market.
• Integration of Artificial Intelligence (AI): Incorporating AI in blood screening processes enhances data analysis, interpretation, and diagnostic accuracy, contributing to market expansion.
• Preventive Healthcare Practices: Growing emphasis on preventive healthcare encourages regular health check-ups, including blood screening, boosting market demand.
• Increased Funding for Research: Investments in research and development activities focused on improving blood screening technologies foster market growth and innovation.
• Rising Incidence of Chronic Diseases: The global increase in chronic diseases necessitates frequent blood screening, sustaining market growth.
• Home-Based Testing Kits: The availability of user-friendly blood screening kits for home use contributes to market growth by promoting accessibility and convenience.
• Awareness Campaigns: Public awareness campaigns about the significance of blood screening drive demand and market growth.
• Expanded Applications: Diversification of blood screening applications beyond routine check-ups, such as genetic screening, expands the market's scope.
• Collaborations and Partnerships: Collaborative efforts between healthcare organizations and industry players foster innovation and drive market expansion.
• Regulatory Support: Stringent regulatory frameworks ensure the quality and safety of blood screening products, fostering trust and market growth.
• Remote Patient Monitoring: Increasing adoption of remote monitoring technologies amplifies the need for efficient blood screening, supporting market growth.
• Patient-Centric Approach: A shift toward patient-centric healthcare models emphasizes personalized diagnostics, stimulating growth in the blood screening market. 
• Abbott Laboratories' annual revenue for 2021 was $43.075 billion, which was a 24.47% increase from 2020. In 2020, Abbott's revenue was $34.608 billion, which was an 8.48% increase from 2019.

Market Scope

Market Dynamics

Driver

Increasing disease prevalence and government initiatives

Increasing disease prevalence and government initiatives play pivotal roles in surging the demand for blood screening in the healthcare market. As the global burden of diseases continues to rise, especially with the growing incidence of cardiovascular conditions, cancers, and infectious diseases, there is an escalating need for early detection and proactive healthcare measures. This trend is a key driver for the blood screening market, as routine screenings enable timely intervention and management of these health issues. Government initiatives further amplify market demand by promoting regular health check-ups and implementing screening programs.

Supportive healthcare policies, public health campaigns, and strategic investments contribute to creating awareness and facilitating easier access to blood screening services. Governments worldwide recognize the significance of preventive healthcare, and their proactive measures not only address the rising disease prevalence but also bolster the overall growth and accessibility of blood screening, thereby enhancing public health outcomes.

Restraint

Ethical concerns and infrastructure challenges

Ethical concerns and infrastructure challenges pose significant restraints to the blood screening market. Ethical considerations, particularly regarding the use of genetic information, may lead to hesitancy among individuals, impacting their willingness to undergo certain blood screening tests. Concerns about potential discrimination based on screening results further contribute to reservations about participating in screening programs. Infrastructure challenges, especially in developing regions, hinder the seamless integration of advanced blood screening technologies. Inadequate healthcare infrastructure limits accessibility to screening services, particularly in rural areas where the availability of sophisticated diagnostic tools and trained healthcare professionals may be scarce. The lack of proper infrastructure also impedes the efficient collection, processing, and analysis of blood samples, affecting the overall effectiveness of screening programs. Addressing these ethical and infrastructural barriers is essential for ensuring equitable access to blood screening services and realizing the full potential of early disease detection and prevention.

Opportunity

Point-of-care testing expansion and disease-specific screening programs 

The expansion of point-of-care testing (POCT) in the blood screening market creates significant opportunities by addressing the growing demand for convenient and immediate diagnostics. POCT enables real-time results, reducing turnaround times and facilitating quicker decision-making in healthcare settings. This trend opens avenues for increased accessibility to blood screening, especially in remote or resource-limited areas, and enhances patient engagement by providing timely and on-the-spot diagnostic information. Furthermore, the development of disease-specific screening programs is a strategic opportunity in the blood screening market. Tailoring screening initiatives to target specific diseases, whether genetic disorders or infectious diseases, allows for more precise and targeted diagnostic approaches. This not only enhances the effectiveness of blood screening but also contributes to a proactive healthcare approach, emphasizing early detection and intervention. The customization of screening programs aligns with the broader trend of personalized medicine, presenting opportunities for specialized diagnostic services that cater to the unique needs of individuals and specific health conditions.

Technology Insights

In 2023, the NAT segment had the highest market share of 41% on the basis of the technology. The Nucleic Acid Amplification Test (NAT) segment in the blood screening market involves the detection of genetic material, providing highly sensitive and specific results. NAT has gained prominence due to its effectiveness in detecting infections, including HIV and hepatitis, with improved accuracy. As a trend, the increasing demand for early detection of infectious diseases and the continuous advancements in molecular diagnostics contribute to the growth of the NAT segment. Its ability to identify infections during the early stages enhances its utility in blood screening protocols, supporting comprehensive healthcare initiatives.

The ELISA segment is anticipated to expand at a significant CAGR of 12.1% during the projected period. Enzyme-Linked Immunosorbent Assay (ELISA) is a widely used technology in the blood screening market. It involves detecting antibodies, antigens, or proteins using an enzyme reaction. ELISA's high sensitivity and specificity make it valuable for disease detection and monitoring. A trend in ELISA technology involves continuous refinements, enhancing its precision and efficiency. Advancements such as automated ELISA systems and multiplexing capabilities are gaining prominence, allowing simultaneous analysis of multiple biomarkers. These trends contribute to the overall growth and utility of ELISA in blood screening applications.

Product Insights

According to the product, the reagent segment has held a 73% revenue share in 2023. In the blood screening market, the reagent segment encompasses essential substances used in diagnostic tests to elicit specific reactions for accurate results. Reagents play a pivotal role in various blood screening assays, including those for infectious diseases and blood typing. A notable trend in this segment involves continuous advancements in reagent formulations to enhance sensitivity, specificity, and overall test performance. Manufacturers are focusing on developing innovative reagents that contribute to the precision and efficiency of blood screening processes, meeting the increasing demand for reliable diagnostic solutions in healthcare settings.

The instruments segment is anticipated to expand fastest over the projected period. In the blood screening market, the instruments segment refers to the hardware and equipment used for analyzing blood samples. This includes sophisticated analyzers, diagnostic tools, and testing devices essential for conducting various blood screening tests. A notable trend in this segment involves continuous technological advancements, leading to the development of high-throughput analyzers and point-of-care testing instruments. These innovations aim to enhance the accuracy, efficiency, and accessibility of blood screening, catering to the growing demand for rapid diagnostics and improving overall healthcare outcomes.

Blood Screening Market Companies

• Abbott Laboratories
• Roche Diagnostics
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Ortho Clinical Diagnostics
• Grifols
• BioMérieux SA
• Siemens Healthineers
• Becton, Dickinson and Company (BD)
• Quest Diagnostics
• Beckman Coulter (now part of Danaher Corporation)
• Bio-Techne Corporation
• F. Hoffmann-La Roche Ltd.
• Quotient Limited
• Sysmex Corporation

Recent Developments

• In March 2023, Abbott secured clearance from the U.S. Food and Drug Administration (FDA) for a groundbreaking laboratory test designed to assess mild traumatic brain injuries (TBIs), commonly known as concussions. This marks the first commercially available lab-based test of its kind, and it will soon be accessible to hospitals nationwide. Utilizing Abbott's advanced Alinity I laboratory tool, this test empowers healthcare professionals to promptly evaluate individuals with mild traumatic brain injuries.
• In May 2023, Siemens Healthcare introduced the Atellica HEMA 570 and 580, representing the next generation of hematology analyzers. These cutting-edge analyzers boast user-friendly interfaces and the capability to connect to multiple analyzers, eliminating workflow barriers and ensuring efficient high-throughput times.

Segments Covered in the Report

By Technology

• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next Generation Sequencing
• Western Blotting

By Product

• Reagent
• Instrument

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa